Hamid Reza Okhravi MD

PubMed

• Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial.
  Tarek K Rajji, Sheriza N Baksh, David M Shade, Zahinoor Ismail, Amer M Burhan
  Nature Medicine. 2025-03-25
• 1 citations
  Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
  Dorene M Rentz, Paul S Aisen, Alireza Atri, Janice Hitchcock, Michael Irizarry
  Alzheimer's & Dementia. 2024-11-01
• 12 citations
  Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
  Olivia Wagemann, Haiyan Liu, Guoqiao Wang, Xinyu Shi, Tobias Bittner
  JAMA Neurology. 2024-06-01

Journal Articles

• Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial  
  Olivia Wagemann 1 2, Haiyan Liu 1, Guoqiao Wang 3, Xinyu Shi 3, Tobias Bittner 4, Marzia A Scelsi 5, Martin R Farlow 6, David B Clifford 1, Charlene Supnet-Bell 1, Ann..., JAMA Neurology, 6/1/2024
• Towards Musculoskeletal Simulation-Aware Fall Injury Mitigation: Transfer Learning with Deep CNN for Fall Detection  
  Haben Yhdego; Jiang Li; Steven Morrison; Michel Audette; Christopher Paolini; Mahasweta Sarkar; Hamid Okhravi, the Institute of Electrical and Electronics Engineers, 4/1/2019
• Skin Angiosarcoma Masquerading as Hematoma in an Elderly Woman  
  Hamid R Okhravi*, Meenal Walia and Robert M Palmer, Journal of Geriatrics and Palliative Care, 3/3/2014

Abstracts/Posters

• Atypical Case of VV1 Creutzfeldt-Jakob Disease subtype
  Adrianna Carrasco, Hamid R. Okhravi, Alzheimer's Association International Conference (AAIC), Chicago, 7/29/2020